# Study of BLZ-100 in Pediatric Subjects With CNS Tumors

Source: https://onco.cc/trials/nct02462629/  
OnCo record `nct02462629` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Tozuleristide run by Blaze Bioscience Inc., completed.

## Summary

Study of BLZ-100 in Pediatric Subjects With CNS Tumors is a phase 1 interventional study registered as NCT02462629 by Blaze Bioscience Inc., with 29 participants enrolled, started 2015-06. Conditions recorded: Central Nervous System Tumors. Interventions recorded: BLZ-100.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02462629
- Phase: 1
- Setting: A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors
- Sponsor: Blaze Bioscience Inc.
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT02462629: https://clinicaltrials.gov/study/NCT02462629

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- drugs: [Tozuleristide](https://onco.cc/drugs/blz-100/)
- companies: [Blaze Bioscience](https://onco.cc/companies/blaze-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct02462629.json